TNXP
TNXP P/E Ratio
P/E Ratio as of Oct 29, 2026: -0.41
Average-0.5123
Median-0.4800
Minimum-0.7500
Maximum-0.4000
-0.41
0.34 (45.33%)past month
The P/E ratio for TNXP is -0.41 as of Oct 29, 2026. This represents a decrease of -21.15% compared to its 12-month average P/E ratio of -0.52. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Tonix Pharmaceuticals Hld P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Tonix Pharmaceuticals Hld’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Tonix Pharmaceuticals Hld to industry peers.
Tonix Pharmaceuticals Hld P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Tonix Pharmaceuticals Hld’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Tonix Pharmaceuticals Hld to industry peers.
TNXP P/E Ratio Insights
See Tonix Pharmaceuticals Hld’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in TNXP
Order type
Buy in
Order amount
Est. shares
0 shares
TNXP P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $9.23 | -0.71 |
| Sep 1, 2026 | $13.98 | -1.08 |
| Aug 3, 2026 | $10.665 | -0.74 |
| Jul 1, 2026 | $12.44 | -0.87 |
| Jun 1, 2026 | $12.29 | -0.86 |
| May 1, 2026 | $13.60 | -0.95 |
| Apr 1, 2026 | $13.68 | -0.96 |
| Mar 2, 2026 | $13.98 | -0.01 |
| Feb 2, 2026 | $17.21 | -0.02 |
| Jan 2, 2026 | $16.55 | -0.02 |
TNXP End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -0.41 | +1,950.00% |
| 2025 | -0.02 | +100.00% |
| 2024 | -0.01 | -75.00% |
| 2023 | -0.04 | -42.86% |
| 2022 | -0.07 | -94.93% |
| 2021 | -1.38 | — |
FAQs About Tonix Pharmaceuticals Hld (TNXP) P/E ratio
The latest P/E ratio of TNXP is -0.41, as of Oct 29, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Tonix Pharmaceuticals Hld’s last 12-month average P/E ratio is -0.52, compared to its current P/E ratio of -0.41. This reflects a decrease of -21.15%.
Tonix Pharmaceuticals Hld’s current P/E ratio of -0.41 is lower than its last 12-month average P/E of -0.52. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Tonix Pharmaceuticals Hld’s average P/E ratio over the last 3 years is -0.23. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Tonix Pharmaceuticals Hld’s average P/E ratio over the last 5 years is -0.32. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
TNXP P/E Ratio Insights
See Tonix Pharmaceuticals Hld’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in TNXP
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.